Abstract
Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy–related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy–related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-19 |
| Number of pages | 19 |
| Journal | JACC: CardioOncology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2025 |
Bibliographical note
Publisher Copyright:© 2025 The Authors
Keywords
- 5-fluorouracil
- Her2 Therapy
- anthracycline
- biomarkers
- cancer survivorship
- cardio-Oncology
- cardiotoxicity
- coronary artery disease
- echocardiography
- guidelines
- heart Failure
- outcomes
- scientific statements
- tyrosine kinase inhibitor
PubMed: MeSH publication types
- Journal Article
- Review
